Skip to main content

Clinical trials

Clinical trials enable health care providers to learn whether a new treatment is safe and effective.

When clinical trials identify new and effective treatments, these treatments will eventually become the new standard of care that will be offered to future patients. Today's standard treatments were researched and proven by clinical trials done in the past. Almost all medications available today have been tested in a clinical trial.

Any time you or a loved one need treatment for cancer, clinical trials are an option to consider. Talk with your oncologist about clinical trials you may qualify for so you can decide what is right for you.

A number of clinical trials are always in progress at Mercyhealth's cancer centers.

Benefits of participating in a clinical trial:

  • Participants receive high-quality cancer care and close observation by the research team.
  • Participants have access to new treatments otherwise not available, which may prove more effective than standard treatment.
  • Participants can help others by improving cancer treatment.
  • Participants may have access to study medication at no cost.

Trials available at Mercyhealth cancer center


  • A011801
    The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib

  • NRG BR004
    A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer

  • SWOG S1703
    Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Rumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer


  • Alliance A021703
    Randomized Double-Blinded Phase III Trial of Vitamin D Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer.
  • GI004
    Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination hemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer


  • EA5163/S1709 INSIGNA
    A randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non?Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature?driven Analysis

    A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)

Multiple myeloma

  • S1803
    Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)

Multiple cancer sites

  • EAY131
    Molecular Analysis for Therapy Choice (MATCH)

  • THR-CS-001
    Detecting cancers Earlier Through Elective plasma-based CancerSEEK testing-Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND2)

Learn more about clinical trials at Mercyhealth

If you'd like more information about your eligibility to participate in a clinical trial, talk to your doctor, email or call Mercyhealth Cancer Center–Janesville at 608.756.6871 or Mercyhealth Cancer Center–Rockford at 815.971.6188.